Full Life is a leading provider of health and wellness solutions that leverage cutting-edge technology to deliver personalized care. With a focus on preventative health, the company offers a range of services including telehealth consultations, wellness tracking, and personalized fitness programs.

Full Life

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

Chengwei Capital

Yunion Health Investments

Sequoia Capital China

CD Capital

Junsan Capital

Kunlun Capital

Guanghua Wutong Fund

Prosperity7 Ventures

Dart Xia Yan Venture Capital

Junson Capital

Sky9 Capital

Summer Capital

Full-Life Technologies

Full-Life Technologies announced the recent achievement of its subsidiary “Full-Life Technology Europe” has obtained a Nuclear Permit for a class IIA facility from the Belgium Federal Agency for Nuclear Control (“FANC”), authorizing the construction and operation of this pivotal facility for producing therapeutic radioisotopes.

#FULLLIFE #NUCLEARPERMIT #FANC #RADIOISOTOPE 

Full-Life Technologies announced that preclinical data of 225Ac-FL-020 (a PSMA-targeted RDC program) will be presented in a Poster Session at the AACR (American Association for Cancer Research) Annual Meeting 2024, which will be held on Apr. 5th to 10th, 2024 in San Diego, CA.

#fulllife #AACR2024 #225Ac #RDC #PSMA

Full-Life Technologies (Full-Life), a clinical stage, fully integrated global radiotherapeutics company and Eckert & Ziegler (ISIN DE0005659700, SDAX) today announced they have entered into an agreement for the supply of Actinium-225 (Ac-225). 

#FullLife #EckertZiegler #Ac225 #SupplyAgreement #radiotherapeutics

Check out Endpoints News' story with Julie Wu, CFO of Full-Life Technologies. 

#FullLife #Radioisotope #Actinium225 #PSMA

Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. 

#FullLife #SeriesB #Prosperity7 #Sky9Capital #SummerCapital #GuanghuaWutongFund #ChengweiCapital #HongShan #JunsonCapital #225Ac-FL-020 #UniRDC™

Metric
Company Name	Full Life
Symbol
MSH ID	COM:FULL-LIFE
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Healthcare Technology
Country	BE
Stage
Employee Count	55
Website	full-life.com
LinkedIn	full-life-technologies
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:FULL-LIFE

Full Life

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue